Answers are grounded in this paper and cite their sources.
Post hoc subgroup analysis investigates tranexamic acid on clinical outcome in aneurysmal subarachnoid hemorrhage, highlighting potential differences across disease grades.
The results of the ULTRA trial showed that ultra-early and short-term treatment with tranexamic acid (TXA) does not improve clinical outcome after aneurysmal subarachnoid hemorrhage (aSAH). Possibly, the lack of a beneficial effect in all patients with aSAH is masked by antagonistic effects of TXA in certain subgroups. In this post hoc subgroup analysis, we investigated the effect of TXA on clinical outcome in patients with good-grade and poor-grade aSAH.
No takes yet. Share an insight, caveat, or question.
Tjerkstra et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: